Tokyo Stock Exchange

MediciNova Receives Gene Therapy Milestone Payment

Retrieved on: 
Thursday, October 5, 2023
Standard Market Design, Tokyo Stock Exchange, Code, AAV, Sales, Fine chemical, Sanofi

LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi.

Key Points: 
  • LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi.
  • The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.

Nidec and Embraer Receive Approval for Joint Venture to Develop Electric Propulsion System for Aerospace Sector

Retrieved on: 
Friday, October 6, 2023
Engineering, Technology, Aerospace, Other Technology, Manufacturing, Other Manufacturing, Eve Air Mobility, Tokyo Stock Exchange, Senior, OTC, NYSE, ERJ, Innovation, EPS, Paris Air Show, Disclosure, UAM, Motion, Embraer, Urban Air Mobility, Advanced Electric Propulsion System, Digital, EVEX, Growth, Strategic management, Aviation, Braley, Management, Cryptocurrency, Nidec

Japan’s Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) and Brazil’s Embraer (B3: EMBR3, NYSE: ERJ) welcome the unconditional approval from all necessary regulatory authorities for the establishment of their joint venture, Nidec Aerospace LLC.

Key Points: 
  • Japan’s Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) and Brazil’s Embraer (B3: EMBR3, NYSE: ERJ) welcome the unconditional approval from all necessary regulatory authorities for the establishment of their joint venture, Nidec Aerospace LLC.
  • The transaction combines the complementary synergies and distinct areas of expertise of two world-class engineering conglomerates to develop Electric Propulsion Systems (EPS) for the aerospace sector.
  • Braley brings broad experience in business development and management to his new role to lead the joint venture’s future growth.
  • Nidec owns a 51% share of the joint venture, and Embraer the remaining 49%.

IPwe Japan and Deloitte Tohmatsu Collaborate to Provide Patent Valuations and Expand Intellectual Property Services

Retrieved on: 
Friday, October 6, 2023
Patent, IP, Investment, Partnership, SIAM, IPW New Zealand Heavyweight Championship, Disclosure, AI, UK Corporate Governance Code, DTFA, Tokyo Stock Exchange, Pharmaceutical industry

NEW YORK, Oct. 6, 2023 /PRNewswire/ -- IPwe Japan K.K. and Deloitte Tohmatsu Financial Advisory LLC (President & CEO: Kazuhiro Fukushima; hereinafter "DTFA"), a Deloitte Tohmatsu Group company, collaborate to provide advisory services focused on patent valuation and supporting IP disclosure.

Key Points: 
  • Alliance to provide advisory services that enhance corporate value through patent valuations and support IP disclosure under the Corporate Governance Code.
  • and Deloitte Tohmatsu Financial Advisory LLC (President & CEO: Kazuhiro Fukushima; hereinafter "DTFA"), a Deloitte Tohmatsu Group company, collaborate to provide advisory services focused on patent valuation and supporting IP disclosure.
  • Recognizing this gap, DTFA, which has long offered patent due diligence and valuation services in Japan, collaborated with IPwe Japan.
  • DTFA and IPwe will further collaborate on reports that can aid in compliance with the Corporate Governance Code's transparency requirements.

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on: 
Thursday, September 28, 2023
ASPR, Code, ALI, Human services, United States Department of Health and Human Services, White lung, Development, MCM, Chlorine, Tokyo Stock Exchange, Biomedical Advanced Research and Development Authority, Acute respiratory distress syndrome, Standard Market Design, BARDA, Safety, Pharmaceutical industry

Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.

Key Points: 
  • Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.
  • The primary endpoint was the pulmonary function measure PaO2/FiO2, which is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
  • In the pilot design single-dose treatment regimen, the test subjects were treated only once after the Cl2 gas challenge was completed.
  • There is a great unmet medical need for treatments for chlorine gas exposure as there is no drug approved specifically for this indication.

Blue Ocean Technologies & Tokyo Stock Exchange Close Strategic Investment Agreement Focused on Expanding Trading Hours for Japanese Investors

Retrieved on: 
Wednesday, September 13, 2023
Partnership, Blue Ocean Strategy, Tokyo Stock Exchange, BOT, TSE, Video game

NEW YORK & TOKYO, Sept. 13, 2023 /PRNewswire/ -- Blue Ocean Technologies , LLC (BOT), a unique capital markets fintech leader in global afterhours trading, and the Tokyo Stock Exchange (TSE) announced today the completion of their strategic partnership agreement and TSE's five percent investment in BOT.

Key Points: 
  • NEW YORK & TOKYO, Sept. 13, 2023 /PRNewswire/ -- Blue Ocean Technologies , LLC (BOT), a unique capital markets fintech leader in global afterhours trading, and the Tokyo Stock Exchange (TSE) announced today the completion of their strategic partnership agreement and TSE's five percent investment in BOT.
  • The deal is focused on expanding access for global investors in Japan and enabling TSE customers to trade US equities on the Blue Ocean ATS during Japanese business day-time hours.
  • Brian Hyndman, President and CEO of Blue Ocean Technologies and Blue Ocean ATS, commented, "We are happy to complete this strategic transaction with the Tokyo Stock Exchange.
  • Blue Ocean Technologies is approximately 35% owned by Urbana Corporation, a Canadian, publicly traded investment company.

Monotype Completes Acquisition of Leading Japanese Foundry Fontworks

Retrieved on: 
Wednesday, September 6, 2023
Catalog, LETS, Acquisition, Tokyo Stock Exchange, Typesetting, Latin, Monotyping

With the completion of this acquisition, Fontworks' extensive font inventory, industry expertise, and dedicated team will enable Monotype to continue to meet the growing demand for high-quality Japanese typefaces from creatives and customers worldwide.

Key Points: 
  • With the completion of this acquisition, Fontworks' extensive font inventory, industry expertise, and dedicated team will enable Monotype to continue to meet the growing demand for high-quality Japanese typefaces from creatives and customers worldwide.
  • Fontworks' catalog includes 'new-classic' Japanese typefaces such as Tsukushi™ and Matisse™- some of Japan's most recognized fonts in media and gaming.
  • Ninan Chacko, CEO at Monotype said, "We're pleased to announce the completion of Monotype's acquisition of Fontworks.
  • Their brand is synonymous with Japanese type and innovation - and as part of Monotype, Fontworks' talented team, market expertise, and catalog will become an integral part of our global type solutions."

EQS-News: Financing secured to complete Taiwan’s 640 MW Yunlin offshore wind farm project

Retrieved on: 
Wednesday, August 30, 2023
Farm, Electricity, Independent power producer, Carbon, Wind, Global Infrastructure Partners, Biofuel, Tokyo Stock Exchange, TotalEnergies, Solar energy, GIP, Renewable energy, Sojitz

Skyborn Renewables (Skyborn), and its partners in Yunneng Wind Power Co., Ltd., TotalEnergies, Electricity Generating Public Company Ltd. (EGCO) and Sojitz Corporation (Sojitz), have successfully secured an extended financing agreement to complete the construction of the 640 MW Yunlin offshore wind farm project in Taiwan.

Key Points: 
  • Skyborn Renewables (Skyborn), and its partners in Yunneng Wind Power Co., Ltd., TotalEnergies, Electricity Generating Public Company Ltd. (EGCO) and Sojitz Corporation (Sojitz), have successfully secured an extended financing agreement to complete the construction of the 640 MW Yunlin offshore wind farm project in Taiwan.
  • “This is a major milestone for the Yunlin project and the offshore wind industry in Taiwan.
  • Once completed, the 640 MW project will be one of the largest offshore wind farms in Taiwan, producing enough clean energy to serve the energy needs of more than 600,000 Taiwanese households.
  • The Yunlin offshore wind farm project is located in the Taiwan Strait, between 8 and 17 kilometers off the west coast of Taiwan, in water depths ranging from 7 to 35 meters.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Friday, August 18, 2023
Co-leaders of the Scottish Green Party, Cleveland Clinic, Code, Case Comprehensive Cancer Center, Clinical trial, SNO, Molecular medicine, Tokyo Stock Exchange, Case Western Reserve University School of Medicine, Poster, Standard Market Design, Pharmaceutical industry, Tobacco, Glioblastoma

LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.

Key Points: 
  • LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.
  • The poster will be presented by MediciNova’s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.
  • The presentation details are as follows:

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Retrieved on: 
Thursday, August 17, 2023
Optical coherence tomography, Patent, Code, Multiple sclerosis, Tablet, Capsule, MD, Tokyo Stock Exchange, OCT, Standard Market Design, MPH, SPRINT, Pharmaceutical industry, Doctor of Philosophy

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.
  • The allowed claims cover a wide range of doses of MN-166 (ibudilast) and a range of different dosing frequencies.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.
  • We are very pleased to receive notice of this new patent which covers Europe, and we believe it could increase the potential value of MN-166.”

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

Retrieved on: 
Wednesday, August 16, 2023
Code, Intellectual property, Scleroderma, Tablet, Canadian Intellectual Property Office, Capsule, Patent, Tokyo Stock Exchange, Standard Market Design, MPH, Pharmaceutical industry

This patent is expected to expire no earlier than June 2035.

Key Points: 
  • This patent is expected to expire no earlier than June 2035.
  • The allowed claims cover the use of MN-001 (tipelukast) for inhibiting or treating scleroderma and/or systemic sclerosis.
  • Ph.D., MPH., Chief Medical Officer, MediciNova, Inc., commented, “This new patent is based on positive results from a systemic sclerosis animal model study conducted recently.
  • We are very pleased to receive notice of this new patent which covers Europe, and we believe it could increase the potential value of MN-001.”